The analysis of antiosteoporotic efficacy of alphacalcidol was made in 50 patients with rheumatoid arthritis (RA). 30 RA patients received alphacalcidol in a dose 0.75-1.0 mcg/day for 12 months. 20 control RA patients did not receive the drug. Mineral density of the bone tissue (MD) of the proximal femur and low back spine was studied using double x-ray absorptiometry at the start of the treatment and 12 months after it. It was established that alphacalcidol stabilizes MD of the neck of the femur and low spine. A significant MD increase was observed in those areas of the proximal femur where cortical bone tissue prevails.